E-mail:support@braincase.cn
Tel:18971216876
Brain CaseBrain Case
  • Home
  • Virus product library
    CRISPRRNAiHSV-helperRV-helperNeurophilic virusCalcium imagingOptogenetics activationOptogenetics inhibitionChemical geneticsFluorescent proteinFluorescent probeRecombinaseApoptosisDisease modelNeurotoxicityOther
  • Products service

    Product center

    Virus

    AAV
    LV
    RV
    HSV
    PRV
    VSV
    RCAS

    Plasmid

    Lentiviral plasmid
    AAV plasmid
    Plasmid Library

    Animal Model

    Neurological Disease Models
    Tumor Model
    Digestive System Disease Model
    Cardiovascular System Disease Model

    Popular applications

    Gene regulation

    Gene Overexpression
    Gene Interference
    Gene Editing

    Neural circuit function research

    Optogenetics
    Chemical Genetics
    Calcium Imaging and Fiber Optic Recording
    GRAB Neurotransmitter Fluorescent Probe
    Functional Magnetic Resonance Imaging Technology

    Research on the structure of neural circuits

    Direct Input and Output Tags
    Anterograde Tracing
    Polysynaptic Anterograde Tracing
    Retrograde Tracing
    Polysynaptic Retrograde Tracing

    Featured Services

    Animal Experiment Outsourcing Service

    Neural circuit studies
    Behavior Test
    Morphological experiment

    Nervous System Disease Drug Effect

    AD
    Depression
    PD
    Epilepsy

    Cell Experiment

    Cell Line Construction
    Dual Luciferase Experiment
    Cell Activity Detection
    Interferon Activity Detection

    Plasmid Construction

    Regular Plasmid
    Bac
    Library Construction

    Virus Packaging

    AAV
    LV
    HSV
    VSV
    RCAS

    AAV Serotype Screening

    AAV Serotype Screening Introduction

    Virus Modification

    RV
    HSV
    VSV

    Oncolytic Virus Construction Service

    HSV
    VSV

    Tumorigenicity Test

    Tumorigenicity Test Introduction

    Model Building

    Others

    Efficacy of Oncolytic Virus

    Oncolytic virus
    Herpes Simplex Virus
    Oral Stomatitis Virus
  • News
    Corporate news New product launch Product promotion Media activities Investor news
  • Support
    Literature interpretation Customer article Data download Video zone FAQs
  • About Us
    Virus product library Products service News Support About Us Contact
  • Contact
    Contact Join us
  • 中文
    English 中文版
  • Home
  • Support
  • Literature interpretation
  • Support
  • Literature interpretation
  • Customer article
  • Data download
  • Video zone
  • FAQs

Xiaobu tips | Targeting strategies of virus tools-Heart Chapter

Release time:2023-02-16 14:33:10

Cardiovascular disease (CVD) has become one of the leading causes of death in the world. Research shows that most heart diseases are related to genetic defects. Gene therapy has become one of the main strategies for preventing and treating CVD in preclinical and clinical research. Gene therapy introduces exogenous normal genes into target cells to correct or compensate for diseases caused by defective and abnormal genes to achieve treatment. Purpose. Recombination Adeno-associated Virus (rAAV) has become the most potential tool vector in gene therapy. It has low immunogenicity, wide host range, many serotypes, and can mediate long-term stable expression of foreign genes. advantage.

In addition, it is also crucial to analyze the structure and connection map of neural networks and reveal how the brain regulates heart function. The trans-synaptic tracking technology of neurotropic viruses can realize the labeling of neural circuits in the heart and central nervous system, providing strong experimental support for research on the mechanisms of cardiovascular diseases.

Here, Xiaobu brings you relevant content on rAAV and neurotropic strategies for use in the heart.

 

1. What are the cardiotropic AAV serotypes?

BrainCase can provide more than 20 rAAV serotypes. Different serotypes have different capsid protein structures, so they have different tropisms for different tissues. AAV serotypes AAV-1, AAV-6, AAV-8, and AAV-9 can efficiently cross the endothelial barrier. In in vivo heart studies, AAV9 and AAV8 serotypes are more effective at infecting the heart than other serotypes, with AAV9 being the predominant type in current studies.

Figure 1 The efficiency of different serotypes and different viral loads in infecting the heart, PMID: 20703310

Virus: rAAV-cTnT-EGFP Injection method: Jugular vein injection Animal model: 1 week old mice Expression time: 4 weeks Injection dose: Figure 1 Specific expression effect of serotype: AAV9>8>6>1>2

 

2. What are the cardiac-specific promoters?

There are many types of cardiac-specific promoters, including cTNT, αMHC, Des, MLC2v, etc. Among them, cTNT and αMHC promoters are widely used.

Figure 2 Efficiency of heart infection with different promoters PMID: 20703310

Virus: rAAV/9-cTnT/CMV-luciferase
Injection method: Jugular vein injection
Animal model: 1 week old mouse
Expression time: 4 weeks
Injection dose: 1×1011 GC/mouse
cardiac-specific promoter Specific expression effect: cTnT> CMV

Figure 3 The efficiency of different promoters in infecting heart (B), skeletal muscle (C) and other tissues (D) PMID: 18811960

Virus: rAAV2/9-CMV/α-MHC/cTnc...-LacZ (galactosidase) Injection method: Superficial temporal vein injection Animal model: Neonatal mice Expression time: 4 weeks Injection dose: 5×1010 GC/ The specific expression effect of mouse cardiac-specific promoter: α-MHC cardiac-specific targeting efficiency is the best, Des is mainly expressed specifically in the heart and skeletal muscle, while CMV is highly expressed throughout the body.

 

3. What viral tools are used for cardiac (peripheral) circuit research?

Neurotropic viruses are a type of virus that are highly sensitive to the nervous system. They have strict neurotropism and can spread and proliferate along specific directions of neural circuits. They are often used to trace the structure of neural networks for information output in the brain center and peripheral areas. Cardiac circuit research focuses on central regulatory circuit research, and PRV is commonly used for retrograde tracing of circuits.

Figure 4 Using PRV to trace SCN-PVN-SCG-sympathetic axis of the heart PMID: 33842566

 

Virus used: PRV-CAG-EGFP
Injection site: Multi-site injection in ventricular myocardium
Experimental animal: Male SD rat
Injection dose: 1×107PFU/mouse
Expression time: 5 days
Tracing results: The heart receives polysynaptic nerves from the SCN Input, there is an anatomical connection between the circadian master pacemaker SCN and the heart, namely the SCN-PVN-SCG-sympathetic axis of the heart.

 

 

4. Comparison of advantages and disadvantages of cardiac virus tool injection methods

 

5. Reference for some usage methods of cardiovirus

 

All the above products/services can be provided by Brinkes.
If other components are required, they can also be customized!
Come and contact Xiaobu

Unauthorized reproduction of this article is prohibited.
If necessary, you can contact Xiaobu (same as WeChat number 18971216876) to obtain the original text.

  • Previous: Xiaobu interprets Nature: Karl Deisseroth, the father of optogenetics, tells you that being too excited can cause anxiety
  • Next: Xiaobu tips | Peripheral PRV tracer - fast, accurate and bright! Everything you want is here!
map
{dede:global.cfg_webname/}

Virus product library

CRISPR
RNAi
Neurophilic virus
Optogenetics activation
Fluorescent probe

Products service

Product center
Featured Services
Popular applications

News

Corporate news
New product launch
Product promotion
Media activities
Investor news

Support

Literature interpretation
Customer article
Data download
Video zone
FAQs
微信

WeChat official account

Tel: 18971216876
E-mail: support@braincase.cn

Address(Wuhan):Room 409, Unit 1, Building F10, Huazhong Zhigu, Haitang Road, Hanyang District, Wuhan City, Hubei Province

Address(Shenzhen):Building A, Mingzhu Campus, Shenzhen University of Technology, Xinhu Street, Guangming District, Shenzhen City, Guangdong Province

  • Copyright © 布林凯斯生物技术股份有限公司 | 鄂ICP备090793554号
  • 互联网药品信息服务资格证书| (鄂)-非经营性-2021-0079